天涯部落

小圈子,大声音!呼朋引伴网聚部落!

创建新部落?

郑州中原区去痘医院哪家好QQ大夫

楼主:大河口碑 时间:2019年11月20日 07:18:21 点击:0 回复:0
脱水模式给他打赏只看楼主阅读设置
A UK-listed company backed by Li Ka-shing, one of Asia’s richest men, says it is moving closer to producing the first modern drug developed in China for decades in a sign of the country’s potential to become a force in the pharmaceuticals industry.由亚洲首富之一李嘉诚(Li Ka-shing)持、伦敦上市的和黄中国医药科技(Hutchison China MediTech,简称:和黄医药)表示,正接近生产几十年来在中国研发的首款现代药物,这一迹象表明中国有望成为制药领域的一生力军。Hutchison China MediTech predicts it will submit its first medicines for regulatory approval next year with several others following behind as the Hong Kong-based company attempts to move beyond traditional Chinese herbal remedies into modern cancer treatments.和黄医药预测,将于明年将其首批药品提交监管部门审批,之后将提交其他药品审批。这家总部位于香港的公司正试图超越中国传统的中草药疗法,进入现代癌症治疗领域。Christian Hogg, chief executive, said Chi-Med was aiming to become China’s first large-scale developer of homegrown innovative pharmaceuticals.和黄医药首席执行官贺隽(Christian Hogg)表示,该公司的目标是成为中国首家本土创新药物的大规模开发者。“For the past 20 years, China has been a passenger in drug development but that is beginning to change,” Mr Hogg told the Financial Times.贺隽告诉英国《金融时报》:“过去20年,中国一直是药物开发领域的乘客,但这点正开始发生变化。”Chi-Med is a subsidiary of Mr Li’s Hutchison Whampoa group and its holding company is listed on London’s junior Aim stock exchange. It has 16 clinical studies under way involving seven experimental medicines for a range of cancers and inflammatory diseases.和黄医药隶属于李嘉诚旗下的和记黄埔(Hutchison Whampoa)集团,其控股公司在伦敦二板市场——另类投资市场(AIM)上市。该公司目前从事16项临床研究,涉及7种实验药物,针对各种癌症和炎症。Mr Hogg said the two most promising of these were on track to be filed for regulatory approval in 2016. Fruquintinib, developed in partnership with Eli Lilly of the US, is targeted at colorectal and lung cancer, while savolitinib, co-developed with AstraZeneca of the UK, is aimed at kidney and gastric cancer.贺隽表示,其中两款最具潜力的药物将在2016年提交监管审批。与美国礼来(Eli Lilly)合作研发的呋喹替尼 (Fruquintinib)用于结肠直肠癌和肺癌的治疗,与英国阿斯利康(AstraZeneca)共同研发的savolitinib旨在治疗肾癌和胃癌。Analysts cautioned that there was no guarantee of success either in clinical trials or in winning share of the fiercely competitive oncology market if approved. But Savvas Neophytou at Panmure Gordon said the company was making faster-than-expected progress. A big increase in research and development investment revealed last week “could shave off up to a year in development time” for fruquintinib, he added.分析师们告诫称,如果获得审批,并不能保该公司会获得临床试验成功,或者在竞争激烈的治癌药物市场成功赢得市场份额。但潘密尔高登(Panmure Gordon)的萨瓦斯#8226;尼奥斐托(Savvas Neophytou)表示,该公司取得的进展快于预期。他补充称,上周公布的研发投资大规模增加,有望将呋喹替尼的“研发时间缩短至多一年”。 /201503/361984

A large new study has documented unexpected links in the timing and severity of symptoms of maternal depression, which could help mothers and doctors better anticipate and treat the condition.一项新的大型研究记录了产妇抑郁症的发作时间与症状严重性之间出人意料的联系,这能帮助产妇和医生更好地预测和治疗这种疾病。The study of more than 8,200 women from 19 centers in seven countries, published last month in Lancet Psychiatry, found that in those with the severest symptoms — suicidal thoughts, panic, frequent crying — depression most often began during pregnancy, not after giving birth, as is often assumed.该研究上月发表在《柳叶刀精神病学》杂志(Lancet Psychiatry)上,它调查了七个国家19个中心的8200多名妇女。研究发现,症状最严重的抑郁症——自杀念头、恐慌、经常大哭——最常在怀期间开始,而非人们通常认为的分娩之后。Moderately depressed women often developed their symptoms postpartum, and were more likely than severely depressed women to have experienced complications during pregnancy like pre-eclampsia, gestational diabetes or hypertension.中度抑郁的产妇通常在产后出现症状,而且与重度抑郁的产妇相比,她们更多地在怀期间经历过先兆子痫、期糖尿病或高血压等并发症。Severely depressed women, however, more often reported complications during delivery.不过,患有重度抑郁症的产妇更常在分娩时出现并发症。“This is the largest study to date on postpartum depressive symptoms,” said Leah Rubin, an assistant professor in the Women’s Mental Health Research Program at University of Illinois at Chicago, a co-author of a commentary about the study. “This is definitely a first step in the right direction, knowing that depression isn’t one-size-fits-all.”“这是迄今为止关于产后抑郁症状的最大型研究,”伊利诺伊大学芝加哥分校女子精神健康研究项目的助理教授利亚·鲁宾(Leah Rubin)说,他曾与人合写了一篇关于这项报告的文章,“知道抑郁症有多种情况,这无疑是通往正确研究方向的第一步。”Ten to 20 percent of mothers experience depression, anxiety, bipolar disorder or other symptoms at some point from pregnancy to a year after giving birth. The study could aid efforts to find causes and treatments.10%至20%的产妇在怀至产后一年的某个时候出现过抑郁、焦虑、躁郁或其他症状。这项研究可以帮助找到原因和治疗方法。The study participants were all mothers. Some had been found to have postpartum depression by clinicians, while others were assessed via a widely used questionnaire. (Some participants fell into both groups.)这项研究的参与者都是产妇。其中一些人的产后抑郁症是临床医生发现的,还有一些是通过被普遍采用的问卷调查评估出来的(有些参与者上述两种情况兼有)。Each group could be separated into three subgroups representing women with severe, moderate, and either mild or clinically insignificant depression, said Dr. Samantha Meltzer-Brody, the director of University of North Carolina’s perinatal psychiatry program and the study’s corresponding author.这项研究的通讯作者、北卡罗来纳大学围产期精神病研究项目的负责人萨曼莎·梅尔策-布罗迪士(Samantha Meltzer-Brody)说,每组可以分成三个小组,分别代表患有重度、中度以及轻度或无临床症状的抑郁症的产妇。Dr. Meltzer-Brody said the finding that two-thirds of severe depression began during pregnancy raised scientific questions. The biological factors at work could differ from those affecting women with classic postpartum depression, which scientists think may be linked to plummeting hormone levels after delivery.梅尔策-布罗迪士说,三分之二的重度抑郁是在怀期间开始的,这个发现引出了一些科学问题。导致怀期间出现抑郁症的生物因素可能与导致典型产后抑郁症的生物因素不同,科学家们认为后者的影响因素可能是分娩后激素水平骤降。She also wondered whether the finding that 60 percent of moderately depressed women reported issues like diabetes suggested that immune system problems might underlie their symptoms.她还说,患有中度抑郁症的产妇60%出现过糖尿病等问题。她想弄清,这一发现是否说明免疫系统问题是抑郁症的诱因。Dr. Meltzer-Brody and her colleagues will begin seeking answers this year by collecting DNA from thousands of women through an international online registry.梅尔策-布罗迪士和她的同事们今年将开始寻找这个问题的,他们计划通过国际在线登记收集上万名妇女的DNA。“Ideally, you could determine who’s at risk,” she said. “What we do now is wait for people to get sick.”“如果一切顺利,我们将能确定哪些人存在风险,”她说,“我们现在在做的事就是等人们生病。” /201503/361987

We want to honor beautiful bodies that break the conventions we encounter in magazines, on television, on billboards and just about everywhere else. The radical and magnificent dance theatre performance Nothing to Lose deconstructs the oppressive body ideals that govern so many of our desires, cherishing the impact of real, human forms. Directed by Force Majeure#39;s Kate Champion, the work is a collaboration with artist and fat activist Kelli Jean Drinkwater.对这些敢于突破常规的艺术家应该给予致敬,他们所展现出的身体之美完全不同于我们在日常的杂志、电视、海报等见到的那样。这组名为“Nothing to Lose”的舞台剧写真激进而又华丽,由凯特·钱皮恩执导,肥胖艺术家及活动家凯利·基恩·德林克沃特合作表演,是对控制我们欲望的受到压迫的身体理想的解放,也是对人类最真实形态的珍视。 /201504/369995

  • 周口市中心医院激光去掉雀斑多少钱
  • 洛阳市额头除皱多少钱当当共享
  • 郑州市妇幼保健儿童医院隆胸多少钱赶集分享
  • 郑州第三人民医院祛痣多少钱
  • 郑州市第五人民医院整形科69热点
  • 巩义市去雀斑多少钱家庭医生解答新乡市开个眼角多少钱
  • 医口碑郑大第一附属医院做红色胎记手术多少钱
  • 安晚报郑州疤痕修复多少钱知道分类
  • 商丘市镭射去痘印价格
  • 郑州市第一人民医院光子嫩肤价钱费用ask大全
  • 郑州颐和医院隆胸多少钱康泰社区郑州巨乳缩小术哪家医院好
  • 郑州/腋臭医院哪里最好
  • 妙手信息漯河市治疗祛斑价格
  • 河南附属医院激光去红血丝多少钱
  • 爱时讯郑州/祛眼袋哪家医院好中医网
  • 88诊疗郑州自体脂肪移植隆鼻哪家医院好
  • 郑州/华山医院祛斑家庭医生知识郑州自体脂肪移植隆胸哪家医院好
  • 咨询诊疗郑州市中医院切眼袋手术多少钱乐视分享
  • 郑州妇保医院整形美容中心搜索社区
  • 新乡市治疗痤疮多少钱
  • 郑州华山医院脱毛多少钱
  • 龙马新闻郑州脱毛好不好
  • 58助手郑州省妇幼保健院激光去黄褐斑价钱费用
  • 郑州华山医疗整形美容医院整形科99网
  • 郑州华山整形美容医院韩式三点多少钱
  • 焦作市人民医院祛眼袋手术多少钱
  • 郑州/市opt嫩肤多少钱
  • 郑州/补处女膜费用天涯热点
  • 豆瓣时讯河南省哪家医院开眼角技术好
  • 河南省郑州华山整形医院整形中心
  • 相关阅读
  • 瞒天过海!集体耕地上建厂房!村民:相关部门集体哑火(三)
  • 暮影战神武灵攻略大全
  • 唐嫣赵丽颖吴昕林允儿李易峰和谁最有感(图)
  • 酒类电商双罢斗
  • 南京查处违规补缴社保证明份购房证明被注销
  • 内蒙古自治区政协原副主席赵黎平一审被判处死刑
  • 近日李念与刚斩获年北京青年电影节影帝的巩峥出现在街边
  • 徐娇穿白袜撑伞古典韵味十足邻家有女初长成
  • 单机斗地主下载:首存优惠
  • 小学生作业本开口说话曝光盗伐林木团伙
  • 相关推荐

    发表回复

    请遵守天涯社区公约言论规则,不得违反国家法律法规